McKesson Revenue Hurt by Supply and Demand Issues for Weight-Loss Drugs

Key TakeawaysMcKesson said that limited access to weight-loss treatments because of short supplies is negatively impacting its services sales.Fiscal 2025 first-quarter revenue was well short of analysts' estimates.McKesson warned of a slowdown in the growth rate for the unit that services patients on weight-loss medications. McKesson (MCK) shares tumbled Thursday, a day after the healthcare services provider warned that limited supply of GLP-1 weight-loss drugs is hurting sales. McKesson reported first-quar ...